The three genes under investigation sit at the heart of synaptic plasticity, the molecular machinery that allows connections between neurons to strengthen or weaken with experience. FMR1 mutations cause Fragile X syndrome, an inherited condition affecting roughly 1 in 4,000 males and 1 in 7,000 females, in which a CGG repeat expansion on the X chromosome silences production of the FMRP protein. FMRP is strongly expressed in neurons of the cortex, hippocampus, thalamus, and cerebellum, and its loss disrupts spine formation and pruning, synaptic plasticity, and protein synthesis. SYNGAP1, by contrast, encodes a protein found in the postsynaptic density, and mutations of this gene account for up to 1 percent of all non-syndromic intellectual disability. GRIN2B governs expression of the GluN2B subunit of the NMDA receptor, a molecular gatekeeper of plasticity itself. All three conditions are associated with IQs of 70 or below in affected males, making them among the most consequential monogenic causes of cognitive impairment known.

Yet when scientists have tried to reproduce these human deficits in rodents, the results have been maddeningly inconsistent. Studies of Fmr1 knockout mice have reported everything from modest water maze impairments to no deficits at all, depending on strain, task, and laboratory. Fmr1 knockout rats have fared no more clearly: one study found fewer platform crossings during probe trials but no difference in quadrant occupancy, while another found no impairment whatsoever in reference memory, reversal learning, or delayed matching to place. The picture in SYNGAP1 models is somewhat more consistent in mice, with impairments reported on T-maze alternation, Barnes maze learning, and water maze probe preference — but even here, some studies found deficits only during the first 15 seconds of a probe trial, with mutant and wild-type mice converging over the full 60 seconds. GRIN2B rodent work has been similarly split, with one mouse study showing impairments in long-term potentiation, long-term depression, and maze performance, while another found no water maze deficits despite a 30 to 50 percent reduction in GluN2B expression.

The research team, led by Anuj Vadher and Paul Dudchenko, suspected that part of the problem lay in the testing paradigm itself. In the traditional Morris water maze, rats swim in a pool of opaque water searching for a submerged platform, using visual landmarks scattered around the laboratory room. But which landmarks the animals actually use — a lantern, a poster, a curtain edge — is assumed rather than demonstrated. The team had recently observed that head direction cells, neurons that putatively underpin the rodent’s sense of direction, show significant alterations in Fmr1 knockout rats. A task that taps the animals’ use of directional information might therefore be especially sensitive to deficits in this model. To make the task genuinely informative, they built a variant in which the only visual landmarks available were four specified objects — a lantern, a white board, a hi-vis jacket, and a sombrero hat — hung on black curtains surrounding the pool. Critically, at the start of each day, the landmarks and the platform were rotated together by a pseudorandom angle, dissociating the platform’s location from any uncontrolled cues in the testing room and rendering the specified landmarks the only reliable external guides.

The pilot work also revealed an unexpected behavioral wrinkle. When tested in an open pool, both mutant and wild-type Fmr1 rats developed an annular search strategy, swimming in circles at roughly the correct distance from the pool walls rather than relying on the landmarks. Radial band analysis confirmed that this ring-search preference was statistically significant in both genotypes. Such a strategy requires no landmark learning at all — the animals simply learn the platform’s distance from the walls. To force genuine landmark use, the team added eight transparent acrylic triangular wall inserts to the pool, dividing it into eight alleyways that opened into a central circle. Now the rats could not simply swim in a ring; they had to swim into and out of each alleyway, making the search far more costly and the use of directional information far more apparent.

Across 10 days of training in this directional water maze, all three mutant models learned the task robustly. Fmr1 knockout rats and their wild-type littermates both showed steep decreases in the time needed to find the hidden platform, and in the platform-removal probe trials — in which the platform stayed submerged and held down by magnets for 60 seconds — both groups showed increasing preference for the target octant, the alleyway containing the platform’s direction. By day 4, both genotypes performed significantly above the 12.5 percent chance level. Remarkably, the Fmr1 knockout rats actually showed a small but significant advantage over wild-type animals in acquisition speed, though the authors attribute this to unusually slow wild-type performance on day 3. In the more robust measure of octant bias during probe sessions, there was no difference between the groups at all.

The Syngap1 heterozygous rats told a similar story, with one nuance. Across two cohorts totaling 8 mutant and 11 wild-type animals, both groups learned the platform direction equally well, with no difference in probe trial octant occupancy. Mutant rats did take slightly longer to find the platform during training — a significant overall genotype effect — but this latency difference never translated into a memory deficit when the platform was removed. The Grin2b heterozygous rats, tested with both males and females, were indistinguishable from wild-type littermates in every measure, and both groups showed significant target octant preference as early as day 2, the fastest learning of any model tested. For a gene whose product directly gates NMDA receptor currents — the very substrate of long-term potentiation — the intact performance is perhaps the most surprising result of the study.

The landmark removal probes delivered the study’s most conceptually significant finding. When three of the four trained landmarks were removed, leaving only one, performance remained above chance for almost every group and almost every landmark, with the exception of the Syngap1 rats, whose preference approached but did not reach statistical significance. Crucially, within each session, some individual animals performed at or below chance while others showed more than 80 percent occupancy of the correct octant. This pattern is inconsistent with configural learning, in which animals triangulate the platform using the full geometry of the landmark array — that strategy would have impaired all animals equally when only one cue remained. Instead, it suggests that different rats had learned directional associations with different individual landmarks, and that each animal’s performance depended on which specific cue happened to survive the deletion. The authors liken this to pattern completion, the same process that keeps hippocampal place fields intact when only a subset of trained landmarks is available.

The implications cut both ways. On one hand, the intact landmark learning in all three models — despite mutations that disrupt RNA binding, postsynaptic signaling, and receptor subunit expression — suggests that basic associative processes are spared in these genetic conditions, and that higher-order tasks involving sensory conflict may be needed to reveal the deficits that clearly exist in affected humans. When a single source of information is sufficient to guide performance, inflexibility in integrating other sensory streams may simply never become apparent. On the other hand, the finding that rats may navigate by individual landmarks rather than landmark configurations — at least in a directional water maze — revises a central assumption of spatial learning research that has gone largely untested for decades. For a field that has long treated the water maze as a window into cognitive map formation, the message is sobering: what looks like map-based navigation may sometimes be a collection of simple stimulus-response associations, each animal carrying its own private compass needle pointed at a single familiar object.

Subject of Research: Intact spatial learning in Fmr1–/y, Syngap1+/–, and Grin2b+/– rat models of neurodevelopmental disorders

Article Title: Intact spatial learning in Fmr1–/y, Syngap1+/–, and Grin2b+/– rat models of neurodevelopmental disorders

Article References: Vadher, A., Duszkiewicz, A. J., Wood, E. R., & Dudchenko, P. A. (2026). Intact spatial learning in Fmr1–/y, Syngap1+/–, and Grin2b+/– rat models of neurodevelopmental disorders. Frontiers in Behavioral Neuroscience, 20, Article 1929983. https://doi.org/10.3389/fnbeh.2026.1929983

Image Credits: AI Generated

DOI: 10.3389/fnbeh.2026.1929983

Keywords: Intact, spatial, learning, Fmr1, Syngap1, Grin2b, models, neurodevelopmental, disorders, scientific research

The syndrome arises from an expansion of CGG repeats in the fragile X messenger ribonucleoprotein 1 gene, or FMR1, on the X chromosome. This expansion silences the gene through hypermethylation, eliminating production of its protein, FMRP. That protein is an RNA-binding molecule with a critical job: it shuttles to both pre- and postsynaptic compartments of neurons, where it fine-tunes local mRNA translation to maintain synaptic plasticity and connectivity. It also influences transcription factors, chromatin-modifying enzymes, and other RNA-binding proteins. When FMRP is absent, the consequences ripple outward, producing the mild cognitive deficits, hyperactivity, and autistic-like behaviors seen in both patients and the widely used Fmr1 knockout mouse model.

Previous work from the same group had already shown that inhibiting CB1, the main receptor of the endocannabinoid system, improves cognitive performance in fragile X mice. Low doses of rimonabant, a selective CB1 antagonist, resolved the aberrant mGluR5-dependent long-term depression and the abnormal hippocampal spine density characteristic of the model. What remained unknown was the molecular machinery underlying those improvements. The new study, led by Lucía de los Reyes-Ramírez and Andrés Ozaita of the Universitat Pompeu Fabra in Barcelona, together with bioinformatician Eduardo Eyras, set out to find that machinery by looking somewhere no one had looked before: inside the synaptoneurosomes, the tiny sealed vesicles that capture both sides of a neuronal connection.

Synaptoneurosomes are essentially pinched-off synaptic terminals, preserving the pre- and postsynaptic machinery in a single preparation. Because FMRP is highly concentrated at synapses, the team reasoned that these structures would offer a far more sensitive window into fragile X pathology than bulk brain tissue. To test this, they split single hippocampi from wild-type mice into two fractions, one processed as bulk homogenate and one enriched for synaptoneurosomes, and sequenced the RNA from both. The fractionation method, not the individual mouse, emerged as the dominant factor shaping the transcriptome. Compared with bulk tissue, synaptoneurosomes were enriched for 749 genes and depleted of 1,019, with the enriched set dominated by Gene Ontology terms related to synapses, transmembrane transport, and mitochondrial activity. More than half of the enriched biological processes were tied to synaptic organization, synaptic plasticity, and mitochondrial bioenergetics, confirming that the preparation genuinely concentrates the synaptic transcriptome.

With that foundation in place, the researchers turned to fragile X mice. Comparing synaptoneurosomes from knockout animals with those of wild-type littermates revealed 29 upregulated and 19 downregulated genes, including changes in genes linked to dendritic arborization, ERK signaling, synaptic transmission, and mTORC1 signaling. The team then treated fragile X mice with rimonabant at 0.1 milligrams per kilogram for seven days, a dose and schedule previously shown to improve cognitive performance and synaptic plasticity. The drug modified the expression of 14 genes in fragile X synaptoneurosomes, and crucially, three of them, Mff, Hnrnpd, and Slain2, moved in the opposite direction to the fragile X signature, effectively reverting toward normal. Quantitative PCR in a larger independent cohort confirmed the reversal for Mff and the fragile X downregulation of Hnrnpd, an RNA-binding protein involved in synapse formation and plasticity. Strikingly, none of these changes appeared when the same animals’ bulk hippocampal tissue was analyzed, underscoring how easily synaptic signals are diluted in whole-tissue preparations.

Because Hnrnpd encodes a direct regulator of mRNA, the team next examined the data at the level of individual transcripts rather than genes, a finer-grained approach that captures the different versions a single gene can produce. This differential transcript expression analysis revealed 254 transcripts altered in fragile X synaptoneurosomes, with enrichment in synapse structure and organization and, notably, in mRNA processing and RNA splicing. Splicing factors such as Celf2 and members of the Hnrnp family were among the downregulated transcripts. When rimonabant was given to fragile X mice, 211 transcripts changed, and the upregulated set was enriched for synapse organization, mRNA splicing, and neuron differentiation, including transcripts from spliceosome-associated genes such as Samd4b, Acin1, and several Hnrnp family members. In wild-type mice, rimonabant produced a completely different and functionally unremarkable pattern, demonstrating that the drug’s effects on the synaptic transcriptome are genotype dependent.

The overlap between the two comparisons was the study’s most striking quantitative result. Of the 254 transcripts altered in fragile X synaptoneurosomes, 34 percent shifted in the opposite direction after rimonabant treatment. More than half of the transcripts downregulated in fragile X animals, 59 out of 109, were restored by the drug, a statistically robust rescue confirmed by hypergeometric testing. Every Gene Ontology term associated with those rescued transcripts related to mRNA processing and splicing, reinforcing the idea that rimonabant ameliorates fragile X synaptic defects by acting on the splicing machinery itself.

That hypothesis was put to a direct test by mapping the alternative splicing landscape, the pattern by which exons are included, skipped, or reconnected to generate different protein isoforms. The absence of FMR1 dysregulated the splicing of 206 genes through 259 alternative splicing events, with alternative first exons and skipped exons the most prevalent categories. Among the affected genes were Cpeb2, FosB, Arf4, Cacng5, and Vdac3, all implicated in synaptic transmission or morphology. Rimonabant modified 178 splicing events in 130 genes in fragile X synaptoneurosomes, and 77 events across 56 genes were common to both the genotype and treatment comparisons, moving in opposite directions. Cross-referencing those 56 genes with a single-cell hippocampal atlas showed that roughly two-thirds are predominantly expressed in neurons, and the affected genes spanned RNA processing, cytoskeleton modulation, ion channels, neuronal development, and mitochondrial function. Most of these events were not significantly altered in rimonabant-treated wild-type mice, indicating a genetic context-specific rescue.

To validate these findings independently, the team designed custom TaqMan probes for three RNA-binding proteins, Ddx6, Celf1, and Cpeb2, and measured both the inclusion and exclusion isoforms of each splicing event in a new, larger set of samples. Ddx6 exon inclusion was downregulated in fragile X synaptoneurosomes and restored by rimonabant, with matching results for exon exclusion. Celf1 transcripts were significantly more abundant after treatment, and Cpeb2 exon inclusion, reduced in fragile X animals, was restored by the drug. The Cpeb2 event was particularly compelling: inclusion or exclusion of a 90-base-pair exon yields two isoforms that differentially regulate RNA translation, and the inclusion isoform is linked to translation activation while the exclusion isoform represses it. Because Cpeb2 controls the translation of neuron-specific mRNAs essential for synaptic plasticity, the researchers propose that its splicing rescue could help normalize the excessive local protein synthesis thought to underlie fragile X synaptic deficits. None of these isoform changes appeared in bulk hippocampal homogenates.

The authors are careful to frame the mechanism as indirect. Given the genes bearing splicing events, FMRP is unlikely to be a direct splicing regulator; instead, it appears to mediate RNA processing by controlling other downstream RNA-binding proteins, many of them brain-specific, that in turn govern synaptic transmission. By restoring the splicing patterns of proteins like Celf1 and Cpeb2, CB1 inhibition may trigger a cascade that normalizes the synaptic microenvironment, potentially including the excitatory-inhibitory balance that is a common feature of autism and fragile X. The study has limitations: only male mice were used, the enriched synaptic fraction may contain other cell types, rimonabant was withdrawn from clinical use and remains an experimental tool, and the splicing changes detected by high-throughput sequencing were subtler when validated by qPCR. Even so, the work establishes that the endocannabinoid system actively modulates the synaptic splicing machinery, and that a previously invisible layer of RNA regulation at the synapse may be a critical step in rescuing fragile X phenotypes. Further studies will determine whether these RNA changes translate into specific protein isoforms capable of restoring fragile X synaptic physiology in humans.

Subject of Research: Restoration of synaptic alternative splicing by CB1 receptor inhibition in a fragile X syndrome mouse model

Article Title: CB1 receptor inhibition restores synaptoneurosomal alternative splicing landscape in fragile X syndrome mice

Article References: Reyes-Ramírez, L. D. L., Ciaran-Alfano, L., Reixachs-Solé, M., Bergadà-Martínez, A., Galera-López, L., Martínez-Torres, S., Navarro-Romero, A., Maldonado, R., Eyras, E., & Ozaita, A. (2026). CB1 receptor inhibition restores synaptoneurosomal alternative splicing landscape in fragile X syndrome mice. iScience, 29(11), Article 117793. https://doi.org/10.1016/j.isci.2026.117793

Image Credits: AI Generated

DOI: Not provided

Keywords: fragile X syndrome, CB1 receptor, rimonabant, alternative splicing, synaptoneurosomes, FMRP, endocannabinoid system, RNA-binding proteins, hippocampus, autism spectrum disorder, transcriptomics, synaptic plasticity

Fragile X syndrome affects roughly 100,000 Americans and is the most common inherited cause of intellectual disability. The disorder stems from changes affecting the FMR1 gene, which disrupts production of FMRP, a protein essential for normal brain development and function. Without adequate FMRP, the brain’s neural circuits develop and operate abnormally, producing a constellation of symptoms that includes intellectual disability, difficulties with learning and memory, social and behavioral challenges, and unusual sensitivity to sensory stimuli such as sound and touch. Fragile X is also recognized as a major genetic contributor to autism spectrum disorder, making advances against the condition relevant far beyond its own patient population.

The central obstacle the collaboration hopes to overcome is one that has frustrated neurologists for decades: the blood-brain barrier. This highly selective interface between the bloodstream and brain tissue blocks the passage of most large molecules, including proteins, which means that even a perfectly designed therapeutic protein is useless if it cannot reach its target cells. Binder explained that Bowen’s FX Therapeutics has used protein engineering to develop versions of the Fragile X-related protein that can be administered systemically, meaning through the bloodstream, and still cross the blood-brain barrier. Once inside the brain, the engineered proteins are designed to replace the function of the protein that is missing or impaired in people with the disorder.

For Binder, the project represents a convergence of two research threads that have matured in parallel: his own years of work characterizing abnormal brain activity in Fragile X, and recent breakthroughs in protein delivery technology. He expressed astonishment at how far the field has come. According to Binder, his collaborators can now engineer a protein and get it into the brain and into cells, something that a few years ago would have seemed like science fiction. That capability, he suggested, transforms what was once a purely observational research program into one that can actively test a potential therapy.

The testing platform for the study is the Fragile X knockout mouse, a well-established animal model in which the gene responsible for the disorder has been removed. These mice exhibit several brain abnormalities that closely resemble those observed in people with Fragile X, including changes in how the brain processes sensory information and how it coordinates neural activity across regions. Because the model recapitulates key features of the human condition, it provides a rigorous preclinical setting in which a candidate therapy can be evaluated before any consideration of human trials.

Binder’s laboratory brings to the collaboration a particular strength in measuring brain activity in living animals, an expertise built over years of studying Fragile X and epilepsy. One of the lab’s principal tools is electroencephalography, or EEG, a technique that records electrical signals generated by neural populations. Rather than examining brain tissue in isolation, the team monitors the whole animal as it behaves and processes stimuli, with the goal of obtaining very high-quality brain recordings from the mice. This approach captures brain function in its natural, dynamic context, which is precisely where the symptoms of Fragile X manifest.

Critically, the lab has already identified specific EEG abnormalities in Fragile X mice, and those measurements now serve as a baseline for the therapeutic study. The logic of the experiment is elegant in its simplicity: if the engineered proteins are doing their job, the characteristic signatures of abnormal brain activity should diminish, and the electrical patterns of treated Fragile X mice should shift toward those of normal mice. Binder and Carrie Jonak, a research associate in the laboratory who generated the preliminary data supporting the grant application and will carry out much of the research, have a straightforward measure of success. As Binder put it, if the Fragile X mice after treatment begin to resemble the normal mice, and their physiology is essentially normalized, that would be a very significant result.

The pilot study is deliberately scoped as a first step rather than a definitive test of clinical benefit. It will not directly determine whether treated mice become better at learning or remembering, since cognitive and behavioral assessments fall outside the one-year project’s scope. However, the researchers argue that brain physiology is upstream of behavior: if the treatment corrects the electrical abnormalities in neural circuits, Binder said his team would predict that some of the associated cognitive and behavioral problems could also improve. In this way, EEG normalization serves as an early, quantifiable biomarker of therapeutic effect, potentially accelerating the path toward more comprehensive studies.

Beyond its scientific promise, the project is also a case study in how targeted foundation funding can bridge the gap between academic neuroscience and biotechnology. Binder framed the collaboration as an example of how foundation support can bring together complementary partners that would not otherwise connect. Bowen’s FX Therapeutics provides access to a promising therapeutic technology, while his laboratory contributes expertise in measuring brain activity in living animals. As he noted, academics would not necessarily have access to these kinds of therapeutics on their own. For a disorder that has resisted every conventional pharmacological approach, the combination of engineered proteins capable of crossing the blood-brain barrier and sensitive physiological readouts in a validated animal model offers a genuinely new strategy, and one whose first results could reshape expectations for treating Fragile X syndrome.

Subject of Research: Protein-based therapy research for Fragile X syndrome

Article Title: Testing a new approach to treating Fragile X

Article References: Testing a new approach to treating Fragile X. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Fragile X syndrome, FMR1 gene, FMRP, protein engineering, blood-brain barrier, electroencephalography, mouse model, FRAXA Research Foundation, UC Riverside, neuroscience, autism spectrum disorder, biotechnology

The study, led by Walter E. Kaufmann of the Department of Human Genetics at Emory University School of Medicine and Paul S. Horn of the Division of Neurology at Cincinnati Children’s Hospital Medical Center, together with the FORWARD Consortium, drew on the pediatric FORWARD database, a multi-site registry and longitudinal clinical database established to study fragile X syndrome across specialty clinics in the United States. The analytical sample comprised 1,072 males and 338 females, an unusually large cohort for a rare genetic disorder, allowing the researchers to examine patterns of co-occurrence with a statistical power that smaller, single-center studies could not achieve.

The team focused on the eight most common behavioral comorbidities identified by clinicians in these specialty fragile X clinics: attention problems, anxiety, hyperactivity, autism spectrum disorder, mood disturbances, irritability and aggression, self-injurious behavior, and sleep problems. Importantly, the researchers treated these as clinician-identified behavioral concerns rather than formal diagnoses, with one exception. Autism spectrum disorder was the only comorbidity defined using explicit DSM-5 criteria, reflecting the particular diagnostic challenges that autism presents in fragile X syndrome, where the social and repetitive features of the syndrome itself can blur the boundary between behavioral phenotype and co-occurring condition.

Across the cohort, attention problems and anxiety emerged as the two most frequent behavioral comorbidities, and, notably, also as the mildest in terms of functional impact. By contrast, the cluster of disruptive behaviors captured under the umbrella of irritability, aggression, agitation, and self-injurious behavior, while less universally present, carried substantially greater weight in terms of impairment. Roughly half of the children affected by any given behavioral comorbidity showed functional impairment from that condition, a proportion that underscores how often these difficulties cross the threshold from trait to clinically meaningful problem in fragile X syndrome.

The most striking finding concerned co-occurrence. Among children with fragile X syndrome, 69 percent were reported to have impairing behavioral comorbidities occurring together, and 39 percent of those children presented with more than two comorbidities simultaneously. Children with multiple co-occurring conditions showed the greatest overall impairment, a dose-response-like pattern suggesting that the cumulative behavioral load, rather than any single diagnosis, is what most powerfully determines how much a child’s daily functioning is compromised. For families and clinicians, this finding reframes fragile X syndrome not as a condition with one dominant behavioral complication but as one in which multiple behavioral challenges frequently compound one another.

To dissect these patterns, the researchers deployed an unusually rich statistical toolkit. Chi-square analyses quantified how frequently pairs of comorbidities appeared together. Polychoric and polyserial correlations, methods designed to estimate the association between ordinal and continuous variables that underlie observed categorical ratings, allowed the team to measure the strength of association between comorbidities while correcting for the fact that co-occurrence is partly driven by simple frequency. Mann-Whitney tests compared behavioral scale scores between groups. This distinction between frequency-driven co-occurrence and genuine statistical association proved crucial: the researchers found that while which comorbidities co-occur is influenced by how common each one is, the strength of the association between any pair was relatively independent of frequency, implying that some pairings reflect shared underlying mechanisms rather than mere arithmetic.

Two of those strong associations stood out because they replicate well-documented patterns in the general, non-fragile X population. The first was the pairing of attention problems with hyperactivity, a combination familiar from attention deficit-hyperactivity disorder in typical development. The second was the coupling of anxiety with mood disturbances, echoing the extensive literature on comorbidity between anxiety and mood disorders in the general psychiatric population. That these canonical pairings also hold in fragile X syndrome suggests that at least some of the architecture of behavioral comorbidity in this genetic condition mirrors the structure seen in the broader population, even though the underlying biology is profoundly different.

The team also examined how standardized behavioral scale scores related to the clinician-identified comorbidities. Scale scores broadly aligned with other severity parameters, lending convergent validity to the clinician-based classification. However, correlations between comorbidities and specific scales tracked the relevance of the behaviors each scale evaluates, rather than behaving as simple proxies for severity. In other words, a given scale correlated most strongly with the comorbidities whose symptom content it directly captures, a finding that helps clinicians interpret behavioral checklist data in fragile X syndrome with appropriate nuance.

Perhaps the most unexpected result of the entire analysis was the discovery that all eight behavioral comorbidities were strongly correlated with the Sensory problems scale. Sensory difficulties, including hyperarousal to sound, touch, and visual stimuli, have been increasingly recognized as central features of fragile X syndrome, with prior work from the FORWARD registry documenting their prevalence and their links to hyperarousal. But the uniformity of the association across such clinically distinct comorbidities, from attention deficits to aggression to sleep disturbance, was not anticipated. The finding raises the possibility that sensory dysregulation functions as a transdiagnostic factor in fragile X syndrome, a common physiological substrate that feeds into or amplifies virtually every major behavioral problem the condition produces. If confirmed by future longitudinal work, this would carry direct therapeutic implications: interventions targeting sensory hypersensitivity and hyperarousal might yield benefits across a wide swath of behavioral comorbidities simultaneously, rather than requiring separate treatments for each condition.

The authors caution that their data are cross-sectional and clinic-based, drawn from children evaluated at specialty fragile X clinics and therefore not necessarily representative of the full population spectrum of the disorder, which includes individuals with milder presentations never referred to specialty care. Even so, the scale of the FORWARD database and the consistency of the findings give the profiles considerable weight. The research team suggests that the reported profiles of impairing behavioral comorbidities could assist clinicians in the early identification of behavioral symptoms in children with fragile X syndrome and in refining the management of those symptoms, and, they add, perhaps in other neurodevelopmental disorders as well, where multi-comorbidity burdens are similarly common and similarly under-characterized. The study was supported by cooperative agreements and a contract funded by the Centers for Disease Control and Prevention, and de-identified data from the FORWARD project are available under the project’s data sharing plan and CDC policies, opening the door for further analyses of how these behavioral trajectories unfold over time.

Subject of Research: Behavioral comorbidities and their co-occurrence patterns in children with fragile X syndrome

Article Title: Profile of Behavioral Comorbidities in Children With Fragile X Syndrome

Article References: Kaufmann, W. E., Horn, P. S., FORWARD Consortium, Berry-Kravis, E., Velinov, M., Talboy, A. L., Sherman, S. L., Kaufmann, W. E., Schuster, M., Tartaglia, N., Filipink, R. A., Budimirovic, D. B., Barbouth, D., Lightbody, A., Reiss, A., Delahunty, C. M., Hagerman, R. J., Hessl, D., Erickson, C. A., … Morris, S. M. (2026). Profile of Behavioral Comorbidities in Children With Fragile X Syndrome. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-026-07525-8

Image Credits: AI Generated

DOI: 10.1007/s10803-026-07525-8

Keywords: fragile X syndrome, behavioral comorbidities, anxiety, attention problems, autism spectrum disorder, sensory problems, FORWARD registry, intellectual disability, hyperactivity, self-injurious behavior, neurodevelopmental disorders, FMR1

Fragile X syndrome is caused by the loss or severe reduction of fragile X messenger ribonucleoprotein, commonly known as FMRP. This protein normally helps control the production of many other proteins at synapses, the microscopic junctions through which neurons communicate. When FMRP is absent, synaptic signaling becomes unusually responsive and poorly regulated. The resulting changes can affect learning, memory, attention, sensory processing and social behavior. In humans, fragile X syndrome is also frequently associated with anxiety, hyperactivity, autistic features and seizures, making the disorder biologically complex rather than a condition defined by a single cognitive impairment.

AM6545 belongs to a class of compounds that interact with the endocannabinoid system, a neuromodulatory network that helps regulate communication between neurons. The compound is designed to act on cannabinoid CB1 receptors, which are widely distributed throughout the brain and are involved in controlling the release of several neurotransmitters. Unlike cannabis-derived compounds that can directly activate CB1 receptors and produce psychoactive effects, AM6545 has been investigated as a negative allosteric modulator. In technical terms, it binds to a regulatory site on the receptor and changes how the receptor responds, potentially reducing excessive signaling while avoiding the full pharmacological profile of a conventional CB1 antagonist.

That distinction matters because the endocannabinoid system is deeply involved in synaptic plasticity, the capacity of neural connections to strengthen or weaken in response to experience. Synaptic plasticity is considered a cellular foundation for learning and memory. In fragile X syndrome, however, the balance between excitation and inhibition in neural circuits can be disrupted, and several studies have implicated abnormal endocannabinoid signaling in that imbalance. By modifying CB1 receptor activity, AM6545 may influence the release of neurotransmitters and help restore more stable communication within circuits involved in cognition. The new research indicates that this process is not limited to cannabinoid signaling itself.

The study by de los Reyes-Ramírez, Bergadà-Martínez, Martínez-Torres and colleagues identifies serotonergic signaling as a mechanism involved in AM6545’s pro-cognitive action in a mouse model of fragile X syndrome. Serotonin, or 5-hydroxytryptamine, is produced by a relatively small group of neurons concentrated mainly in the raphe nuclei of the brainstem. From there, serotonergic projections extend across broad regions, including the hippocampus and prefrontal cortex—areas essential for memory formation, attention and flexible decision-making. Serotonin acts through multiple receptor families, each capable of triggering distinct intracellular responses, so describing a “serotonergic mechanism” does not imply a single universal serotonin pathway.

Instead, the finding suggests that AM6545’s cognitive effects may depend partly on how the compound changes serotonin release, receptor activity or the responsiveness of neural circuits to serotonergic input. This is scientifically significant because serotonin and the endocannabinoid system are not isolated networks. They communicate at several levels: cannabinoid receptors can influence neurotransmitter release from serotonergic terminals, while serotonin receptors can alter the activity of circuits that also receive endocannabinoid regulation. Such cross-talk provides a plausible biological route by which a compound acting at CB1 receptors could produce effects that ultimately require serotonin signaling.

In animal research, evidence for this type of mechanism generally comes from combining behavioral tests with pharmacological or neurobiological interventions that selectively interfere with serotonergic transmission. When a compound improves performance in tasks measuring learning or memory, and that improvement is reduced or eliminated when serotonin receptors or related pathways are blocked, researchers can infer that serotonergic signaling contributes to the observed effect. The study’s central conclusion is therefore not simply that AM6545 changes behavior in a fragile X model, but that its cognitive benefit is linked to a specific neurotransmitter system. That distinction helps move the field from descriptive findings toward a more mechanistic understanding of drug action.

The implications extend beyond one experimental compound. Current clinical management of fragile X syndrome focuses largely on symptoms, using behavioral interventions and medications aimed at problems such as anxiety, attention difficulties, irritability, sleep disruption or seizures. No broadly approved treatment directly corrects the molecular cause of the syndrome or reliably restores cognitive function. A treatment strategy that engages both endocannabinoid and serotonergic biology could eventually offer new options, but the path from a mouse model to human therapy is long. Doses, metabolism, receptor distribution and safety margins can differ substantially between species, and improvements in laboratory tasks do not automatically predict meaningful gains in human learning or daily functioning.

The findings also raise questions that future studies will need to answer. Researchers will need to determine which serotonin receptor subtypes are essential, which brain regions are most important, and whether the response depends on the developmental stage or the severity of fragile X-related abnormalities. It will also be important to establish whether AM6545 improves multiple cognitive domains or primarily affects particular forms of memory, attention or behavioral flexibility. Long-term studies must examine tolerance, emotional effects, motor consequences and possible interactions with medications that already influence serotonin or cannabinoid signaling. These details will determine whether the mechanism is a promising therapeutic avenue or mainly a guide to understanding circuit dysfunction.

For now, the study offers a sharper view of how cognition may be altered in fragile X syndrome and how it might be pharmacologically improved. Its message is not that serotonin alone explains the disorder, nor that AM6545 is ready for clinical use. Rather, it reveals that the cognitive effects of manipulating cannabinoid receptor signaling can depend on communication with the serotonergic system. In a field where complex neurological symptoms arise from the interaction of many molecular pathways, that kind of mechanistic link is valuable. It gives researchers a new target for experiments—and a possible blueprint for designing treatments that aim not merely to suppress symptoms, but to stabilize the neural networks underlying learning and memory.

Subject of Research: Serotonergic mechanisms underlying the pro-cognitive effects of AM6545 in a mouse model of fragile X syndrome.

Article Title: A serotonergic mechanism is involved in the pro-cognitive effect of AM6545 treatment in a mouse model of fragile X syndrome.

Article References: de los Reyes-Ramírez, L., Bergadà-Martínez, A., Martínez-Torres, S. et al. “A serotonergic mechanism is involved in the pro-cognitive effect of AM6545 treatment in a mouse model of fragile X syndrome.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04360-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04360-4

Keywords: fragile X syndrome, AM6545, serotonin, serotonergic signaling, endocannabinoid system, CB1 receptor, cognition, synaptic plasticity, mouse model, neurobiology